Jacobs Levy Equity Management, Inc Arcellx, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $25.8 Billion
- Q4 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Arcellx, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 78,584 shares of ACLX stock, worth $5.37 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
78,584
Previous 79,936
1.69%
Holding current value
$5.37 Million
Previous $6.68 Million
10.35%
% of portfolio
0.02%
Previous 0.03%
Shares
3 transactions
Others Institutions Holding ACLX
# of Institutions
224Shares Held
45.1MCall Options Held
434KPut Options Held
433K-
Paradigm Biocapital Advisors LP New York, NY4.37MShares$299 Million12.7% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$256 Million20.37% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$240 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.48MShares$238 Million8.84% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.33MShares$228 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...